Haldol (Haloperidol)

Haloperidol (Haldol) is indicated for several psychiatric and neurological conditions where dopamine blockade is therapeutic.

• Management of schizophrenia, both chronic maintenance and acute exacerbations.
• Treatment of acute psychosis of various etiologies, such as drug‑induced or brief psychotic disorder.
• Control of manic episodes in bipolar disorder when rapid symptom reduction is needed.
• Rapid calming of severe agitation or aggression in emergency or inpatient settings.
• Reduction of motor and vocal tics in Tourette syndrome and other tic disorders.
• Adjunctive therapy for severe behavioral disturbances in patients with neurodevelopmental disorders.

Haloperidol may cause a range of adverse effects that vary in frequency and severity.

Common

• Drowsiness or sedation, especially when therapy is initiated.
• Extrapyramidal symptoms such as tremor, rigidity, akathisia, or dystonia.
• Dry mouth and increased salivation, which may affect oral comfort.
• Constipation or gastrointestinal discomfort, including nausea.
• Blurred vision or dizziness, often transient.
• Weight gain or changes in appetite, varying among individuals.

Serious

• Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by fever, muscle rigidity, and autonomic instability.
• Tardive dyskinesia, persistent involuntary movements that may become irreversible.
• Severe hypotension or cardiac arrhythmias, particularly in patients with pre‑existing heart disease.
• Seizures or worsening of pre‑existing seizure disorders, requiring monitoring.
• Elevated prolactin levels leading to menstrual disturbances, galactorrhea, or sexual dysfunction.
• Severe allergic reactions such as rash, angioedema, or anaphylaxis, requiring immediate medical attention.

When prescribing haloperidol, clinicians should consider several precautionary measures to minimize risk and ensure safe use.

• Assess cardiovascular status, as haloperidol can cause QT prolongation and hypotension.
• Evaluate for a history of movement disorders, including Parkinson’s disease or prior extrapyramidal reactions.
• Use the lowest effective dose, especially in elderly patients, to reduce sedation and fall risk.
• Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation.
• Check prolactin levels periodically in patients who develop hormonal symptoms.
• Avoid use during pregnancy unless benefits outweigh risks, due to limited safety data.
• Review liver and kidney function, as impairment may affect drug clearance.

Haloperidol can interact with other medications, altering its efficacy or increasing adverse effect potential.

Avoid

• Concurrent use with other strong dopamine antagonists, which may intensify extrapyramidal symptoms.
• Combination with medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Co‑administration with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution

• Concurrent use of CNS depressants (e.g., benzodiazepines, opioids) may increase sedation and respiratory depression.
• Combining with anticholinergic agents can mask early signs of extrapyramidal side effects.
• Use alongside drugs that affect hepatic metabolism (e.g., carbamazepine, rifampin) may reduce haloperidol effectiveness.